David Epstein - Novartis Executive
| NVSN Stock | MXN 1,540 0.00 0.00% |
Executive
Mr. David R. Epstein is Member of the Executive Committee and Division Head, Pharmaceuticals at Novartis AG since February 1, 2010. Prior to his current position, Mr. Epstein served as Head of Novartis Oncology since 2000. He led the Molecular Diagnostics unit of the Company since 2008. He is a permanent attendee of the Executive Committee of Novartis. Before joining Novartis, Mr. Epstein was an associate in the Strategy Practice of the consulting firm, Booz Allen Hamilton. Mr. Epstein joined Sandoz, a predecessor company of Novartis, in 1989, and held various leadership positions of increasing responsibility for the company, including Chief Operating Officer of Novartis Pharmaceuticals Corporation in the United States and Head of Novartis Specialty Medicines since 2010.
| Age | 53 |
| Tenure | 14 years |
| Professional Marks | MBA |
| Phone | 41 61 324 1111 |
| Web | https://www.novartis.com |
Novartis Management Efficiency
The company has return on total asset (ROA) of 0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1093 %, meaning that it generated $0.1093 on every $100 dollars invested by stockholders. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John Finneran | Capital One Financial | 68 | |
| Federico Medellin | Grupo Sports World | N/A | |
| Lia Dean | Capital One Financial | 40 | |
| Roberto Celorio | Grupo Sports World | N/A | |
| Celia Karam | Capital One Financial | 44 | |
| Ana Joachin | Grupo Sports World | N/A | |
| Noelle Eder | Capital One Financial | 47 | |
| Ana Corcuera | Grupo Sports World | N/A | |
| Antonio Rodriguez | Grupo Sports World | N/A | |
| Jesus Gonzalez | Grupo Sports World | 44 | |
| Marco Munoz | Grupo Sports World | N/A | |
| Robert Alexander | Capital One Financial | 58 | |
| Trevor Schulze | Micron Technology | N/A | |
| Brackett Denniston | Cognizant Technology Solutions | 68 | |
| Jory Berson | Capital One Financial | 47 | |
| Sheldon Hall | Capital One Financial | 41 | |
| Roberto Rangel | Grupo Sports World | N/A | |
| Matthew Cooper | Capital One Financial | 50 | |
| Katie Royce | Cognizant Technology Solutions | N/A | |
| Begona Garcia | Grupo Sports World | N/A | |
| Xavier Duenas | Grupo Sports World | 44 | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 |
Novartis AG Leadership Team
Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ton Buechner, Non-Executive Independent Director | ||
| Robert PharmD, Chief Officer | ||
| Verena Briner, Non-Executive Independent Member of the Board | ||
| Karen Hale, Chief Officer | ||
| Chris Ilsley, President CEO | ||
| Steven Baert, Chief People & Organization Officer, Member of the Executive Committee | ||
| Richard Saynor, Chief Executive Officer of Sandoz, Member of the Executive Committee | ||
| Richard Francis, Member of the Executive Committee and Division Head, Sandoz | ||
| Daniel Vasella, Honorary Chairman of the Board | ||
| Pierre Landolt, Member of the Board of Directors | ||
| Elizabeth Doherty, Non-Executive Independent Director | ||
| Erwin Vanhaecke, Head Novartis Group Quality | ||
| Elizabeth Barrett, CEO, Novartis Oncology | ||
| Mark Fishman, Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR) | ||
| Charlotte PamerWieser, Corporate Secretary | ||
| Shannon Klinger, Chief Risk and Compliance Officer, Group General Counsel | ||
| Samir Shah, Global Head Investor Relations | ||
| David Epstein, Member of the Executive Committee, Division Head, Pharmaceuticals | ||
| Srikant Datar, Non-Executive Independent Director | ||
| MarieFrance Tschudin, President of Novartis Pharmaceuticals, Member of the Executive Committee | ||
| Samir MD, Global Relations | ||
| Simon Moroney, Non-Executive Independent Director | ||
| Francesco Balestrieri, CEO of Sandoz, Member of the Executive Committee | ||
| Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee | ||
| Paul Penepent, Head Accounting | ||
| Joerg Reinhardt, Independent Non-Executive Chairman of the Board | ||
| Paul Hudson, CEO of Novartis Pharmaceuticals, Member of the Executive Committee | ||
| Brian McNamara, Member of the Management Board, Division Head, Novartis OTC | ||
| Andrews C, Non-Executive Independent Director | ||
| Michele Galen, Head Communications | ||
| Charles Sawyers, Non-Executive Independent Member of the Board | ||
| John Tsai, Head of Global Drug Development and Chief Medical Officer, Member of the Executive Committee | ||
| Dimitri Azar, Non-Executive Independent Director | ||
| Frans Houten, Non-Executive Independent Director | ||
| Nancy Andrews, Non-Executive Independent Director | ||
| Susanne Schaffert, President of Novartis Oncology, Member of the Executive Committee | ||
| Enrico Vanni, Lead Independent Non-Executive Vice Chairman of the Board | ||
| Bertrand Bodson, Chief Digital Officer, Member of the Executive Committee | ||
| Robert Weltevreden, Head of Novartis Business Services (NBS), Member of the Executive Committee | ||
| Andre Wyss, Member of the Executive Committee, Novartis Business Services and Country President for Switzerland | ||
| Bruno Strigini, CEO of Novartis Oncology, Member of the Executive Committee | ||
| Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee | ||
| Alex Krauer, Honorary Chairman of the Board | ||
| Michael Ball, CEO of Alcon, Member of the Executive Committee | ||
| Jeffrey George, Member of the Executive Committee and Division Head, Sandoz | ||
| Patrice Bula, Non-Executive Independent Director | ||
| Peter Kornicker, Chief Compliance Officer | ||
| Andreas Planta, Non-Executive Independent Director | ||
| Joseph Jimenez, CEO, Member of the Executive Committee | ||
| Ulrich Lehner, Vice Chairman of the Board of Directors, Non-Executive Director | ||
| William Winters, Non-Executive Independent Member of the Board | ||
| Ann Fudge, Non-Executive Independent Director | ||
| George Gunn, Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate Responsibility | ||
| Paul Arkel, Head of Corporate Strategy and External Affairs | ||
| James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee | ||
| Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee | ||
| Felix Ehrat, General Counsel and General Counsel of Novartis International Ag | ||
| Harry Kirsch, Chief Financial Officer, Member of the Executive Committee | ||
| Andrin Oswald, Member of the Executive Committee, Division Head, Vaccines and Diagnostics | ||
| Bridgette Heller, Non-Executive Independent Director |
Novartis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novartis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 4.12 T | |||
| Shares Outstanding | 2.12 B | |||
| Shares Owned By Institutions | 8.23 % | |||
| Price To Earning | 24.95 X | |||
| Price To Book | 2.82 X | |||
| Price To Sales | 74.58 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novartis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novartis' short interest history, or implied volatility extrapolated from Novartis options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Novartis Stock analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |